Connect MM® – The Multiple Myeloma Disease Registry: Incidence of Second Primary Malignancies in Patients Treated With Lenalidomide

Advances in treatment have extended the survival of patients with multiple myeloma (MM), but this increased survival time also increases the potential for developing second primary malignancies (SPM). According to the data from the Surveillance, Epidemiology, and End Results (SEER) Program, the 20-year risk of invasive SPM for patients with MM is 6.1%, which is similar to the overall risk of malignancy in the average patient-based population.


 Leukemia & Lymphoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.